Our top pick for
Beginners

Acceleron Pharma Inc is a biotechnology business based in the US. Acceleron Pharma shares (XLRN) are listed on the NASDAQ and all prices are listed in US Dollars. Acceleron Pharma employs 312 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | $113.49 - $189.99 |
---|---|
50-day moving average | $169.49 |
200-day moving average | $137.95 |
Wall St. target price | $178.88 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-4.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $N/A from 2021-12-08
1 week (2022-06-21) | N/A |
---|---|
1 month (2022-05-29) | N/A |
3 months (2022-03-29) | N/A |
6 months (2021-12-29) | N/A |
1 year (2021-07-02) | -100.00% |
---|---|
2 years (2020-07-02) | -100.00% |
3 years (2019-07-02) | -100.00% |
5 years (2017-06-30) | -100.00% |
Revenue TTM | $112.8 million |
---|---|
Gross profit TTM | $-81,394,000 |
Return on assets TTM | -18.4% |
Return on equity TTM | -31.59% |
Profit margin | -226.01% |
Book value | $11.75 |
Market capitalisation | $10.9 billion |
TTM: trailing 12 months
We're not expecting Acceleron Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $113.49 up to $189.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.1314. This would suggest that Acceleron Pharma's shares are less volatile than average (for this exchange).
Acceleron Pharma Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.